Perjeta (pertuzumab) / Roche 
Welcome,         Profile    Billing    Logout  
 80 Diseases   208 Trials   208 Trials   5617 News 


«12...1011121314151617181920...7172»
  • ||||||||||  Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (BIS-Program) (Exhibition area) -  Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_417;    
    P2
    Two FFPE and one frozen sample are collected at (1) the time of enrollment and (2)following surgical treatment in those who undergo upfront surgery or dedicated biopsy after study treatment in those who undergo NST. Blood samples will be collected at the time of enrollment, before surgery or the start of NST, and at the end of the study visit.
  • ||||||||||  Perjeta (pertuzumab) / Roche
    Updated survival analysis in NEOPERSUR trial: Neoadjuvant Pertuzumab in a real-world population in the south of Spain. (Exhibition area) -  Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_407;    
    Background Pertuzumab (P) has been approved in neoadjuvant setting for HER2-positive early breast cancer patients (pts) in association with Trastuzumab (T) and chemotherapy...The majority of the patient received anthracyclines and taxanes with P and T regimen (77,1%), 16,5% received carboplatin-docetaxel-P-T combination and 6,5% received taxane-P-T...Conclusions In our knowledge, this is the first real-world study that shows survival results for adding Pertuzumab in the neoadjuvant setting of HER2-positive breast cancer patients. Our results are consistent with those previously published.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
    Exploratory biomarker (BM) analyses from IMpassion050 (Exhibition area) -  Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_388;    
    P3
    Conclusions Taken together with the safety and early efficacy, the long-term benefit of the ZoNAnTax regimen demonstrating DFS and OS rates as high as reported by pivotal studies that contained Pertuzumab in the same setting, suggests that adding ZOL as a repositioning drug to the NT of HER2+ BC should be considered. Background In IMpassion050 (NCT03726879), adding atezolizumab (A) to neoadjuvant chemotherapy (CT) and pertuzumab
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Review, Journal:  Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine. (Pubmed Central) -  Mar 21, 2023   
    Excess of Trastuzumab do not block the affinity of labeled affibodies. Silica nanoparticles have been conjugated to anti-HER2 antibodies to enable targeting of HER2 expressing cells with potential of drug delivery carry for antitumor agents and b(beta) or a(alfa) emitting radioisotopes commonly used for radionuclide therapy, as Iodine-131, Lutetium-177, Yttrium-90, Rhenium-188 and Thorium-277.
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche, Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche
    Bridging the gap between clinical-omics and machine learning to improve cancer treatment (Room W414 - Convention Center) -  Mar 14, 2023 - Abstract #AACR2023AACR_7870;    
    More datasets will be continuously added, and new algorithms can be easily benchmarked against existing ones. ClinicalOmicsDB unifies the efforts from the clinical and machine learning communities to improve cancer treatment.
  • ||||||||||  Role of individual HER family members and pan-HER targeting treatment strategy in NRG1 fusion positive cancer (Section 21; Poster Board #16) -  Mar 14, 2023 - Abstract #AACR2023AACR_6231;    
    Treatment with cetuximab, an antibody that targets EGFR, in combination with trastuzumab and pertuzumab yielded a synergistic effect on tumor cell killing. These data indicate that HER4 and EGFR can play a role in NRG1 fusion-driven signaling through crosstalk with HER2/HER3 and thus, pan-HER/EGFR inhibitors are more effective than EGFR/HER2 or HER2/HER4-selective inhibitors, highlighting the therapeutic potential of targeting multiple members of the HER family in NRG1 fusion driven cancers.
  • ||||||||||  TAS2940 / Otsuka
    TAS2940 inhibits intracranial tumor growth and prolongs survival in HER2-aberrant and EGFR-amplified patient-derived xenograft models (Section 20; Poster Board #14) -  Mar 14, 2023 - Abstract #AACR2023AACR_6207;    
    P1
    Here, we demonstrate that TAS2940 induces downregulation of phosphorylated HER2/EGFR, reduces tumor burden, and promotes a significant increase in survival in intracranial xenograft mouse models with HER2-amplification (BC), HER2-Exon20 insertion mutation (NSCLC), and EGFR-amplification (GBM). These promising preclinical data highlight potential novel therapeutic strategies for patients with EGFR-aberrant GBM and brain metastases harboring HER2/EGFR alterations, and may help support the advancement of the ongoing first-in-human clinical trial (NCT04982926) for TAS2940 in solid tumors with EGFR and/or HER2 alterations.
  • ||||||||||  Tukysa (tucatinib) / Seagen
    Imaging molecular alterations during tucatinib response in preclinical models of HER2+ breast cancer (Section 19; Poster Board #13) -  Mar 14, 2023 - Abstract #AACR2023AACR_6064;    
    Tucatinib significantly decreases tumor volume and decreases intratumoral proliferation and hypoxia in both cell-line and patient-derived xenograft models of HER2+ breast cancer. Our data suggests molecular imaging may drive understanding of and predict response to tucatinib therapy.
  • ||||||||||  BAT1006 - Bio / Thera Solutions
    A phase I study of BAT1006, a novel anti-HER2 antibody, in patients with locally advanced/metastatic solid tumors (Section 46; Poster Board #2) -  Mar 14, 2023 - Abstract #AACR2023AACR_6010;    
    BAT1006 was well tolerated and showed promising anti-tumor activity in patients with heavily pre-treated HER2-positive cancers. Based on the safety and efficacy results, one additional dose level (20 mg/kg) will be added to the escalation phase and combination therapy with other HER2-based therapy will also be initiated.
  • ||||||||||  trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
    Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study (Section 45; Poster Board #7) -  Mar 14, 2023 - Abstract #AACR2023AACR_5998;    
    Subgroup analyses of ORRNo. of prior treatment lines in metastatic setting in all pts (N=250)HER2 positive BC (N=108)HER2-low BC (N=77)Other tumor types (N=65)?381.8% (45/55)58.7% (27/46)36.7% (18/49)>381.1% (43/53)51.6% (16/31)31.3% (5/16)Prior anti-HER2 therapies in pts with BC (N=185)*HER2 positive BC (N=108)HER2-low BC (N=77)All BC (N=185)Any82.2% (88/107, 73.7-89.0)68.8% (11/16, 41.3-89.0)80.5% (99/123, 72.4-87.1)Trastuzumab81.9% (86/105, 73.2-88.7)75.0% (9/12, 42.8-94.5)81.2% (95/117, 72.9-87.8)Pertuzumab83.0% (39/47, 69.2-92.4)100% (5/5, 47.8-100)84.6% (44/52, 71.9-93.1)Pyrotinib86.9% (53/61, 75.8-94.1)71.4% (5/7, 29.0-96.3)85.3% (58/68, 74.6-92.7)Lapatinib80.0% (28/35, 63.1-91.6)100% (1/1, 2.5-100)80.6% (29/36, 64.0-91.8)T-DM182.4% (14/17, 56.6-96.2)100% (3/3, 29.2-100)85.0% (17/20, 62.1-96.8)Other HER2-ADC (except T-DM1)**60.0% (9/15, 32.3-83.7)50.0% (2/4, 6.8-93.2)57.9% (11/19, 33.5-79.8)ORR in pts with tumor types other than BC (N=65)HER2 IHC3+ or IHC2+/ISH+ (N=36)HER2 IHC2+/ISH- or IHC1+ or unknown (N=29)All other tumor types (N=65)% (n/N)38.9% (14/36)31.0% (9/29)35.4% (23/65)ORR was shown as % (n/N, 95% CI) or % (n/N).
  • ||||||||||  Herceptin (trastuzumab) / Roche, MBQ-167 / MBQ Pharma, Perjeta (pertuzumab) / Roche
    Targeting Rac/Cdc42 GTPases to overcome HER2-targeted therapy resistance (Section 11; Poster Board #6) -  Mar 14, 2023 - Abstract #AACR2023AACR_5237;    
    MBQ-167 reduced Rac activity and downstream signaling, as well as cell viability with a GI50 of 78nM after 72 hours, while caspase activity was increased after 24 hours of treatment. The results presented herein show the utility of the Rac/Cdc42 inhibitor MBQ-167 in overcoming HER2-targeted therapy resistance.
  • ||||||||||  D3L-001 / D3 Bio
    D3L-001, a novel bispecific antibody targeting HER2 and CD47, demonstrates potent preclinical efficacy in solid tumors. (Section 25; Poster Board #12) -  Mar 14, 2023 - Abstract #AACR2023AACR_4019;    
    Many HER2-targeted drugs, including trastuzumab, pertuzumab, lapatinib, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd), have been approved for treatment of HER2-positive early and metastatic breast cancer (BC)...In both in vitro and in vivo studies using breast cancer HCC1954, JIMT-1 and gastric cancer N87 models, we observed a synergistic effect in the combination of Trastuzumab with Magrolimab...D3L-001 also displayed potent and comparable in vivo efficacy as Enhertu in gastric N87 model, and it showed synergistic in vivo efficacy, when combining with Pertuzumab or Paclitaxel, in breast HCC1954, JIMT-1 and gastric cancer N87 models. D3L-001, a novel HER2
  • ||||||||||  sabizabulin (VERU-111) / Veru Inc, Valeo Pharma
    Sabizabulin shows anti-cancer efficacy in HER2+ breast cancer and novel sabizabulin derivatives overcome paclitaxel-resistance in triple negative breast cancer (Section 18; Poster Board #27) -  Mar 14, 2023 - Abstract #AACR2023AACR_3913;    
    While sabizabulin shows promising results for treatment in HER2+ breast cancer, we further optimized the structure of sabizabulin to create a new class of anti-cancer molecules: 40a, CH-2-77, and 60c. Based on in vitro data, 60c showed higher potency in HER2+ breast cancer cell lines and was chosen as the lead compound to further study in a paclitaxel-resistant triple negative breast cancer in vivo study where it was able to effectively inhibit primary tumor growth compared to the vehicle group.
  • ||||||||||  Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Perjeta (pertuzumab) / Roche
    Evaluation of Her2 RNA expression as a potential predictive biomarker for anti-Her2 therapy (Section 39; Poster Board #19) -  Mar 14, 2023 - Abstract #AACR2023AACR_2191;    
    Additionally, 25.8% of all non-breast solid tumors were classified as HER2 RNA Low. Given that HER2 RNA High predicted benefit from 1st generation anti-HER2 therapies, future studies should consider HER2 RNA Low as an alternative biomarker to Her2 IHC Low, with the opportunity to further expand trastuzumab deruxtecan use into the IHC 0+ breast cancer population and potentially to additional solid tumors.
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (clinicaltrials.gov) -  Mar 13, 2023   
    P2a,  N=16, Active, not recruiting, 
    Given that HER2 RNA High predicted benefit from 1st generation anti-HER2 therapies, future studies should consider HER2 RNA Low as an alternative biomarker to Her2 IHC Low, with the opportunity to further expand trastuzumab deruxtecan use into the IHC 0+ breast cancer population and potentially to additional solid tumors. Suspended --> Active, not recruiting | N=50 --> 16 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  5-fluorouracil / Generic mfg.
    Osmotic Demyelinating Syndrome Secondary to Breast Cancer Chemotherapy: a Case Report (Both in-person and online) -  Mar 12, 2023 - Abstract #AAN2023AAN_3402;    
    In another study published by Cortes and colleagues, the development of osmotic demyelinating syndrome when using a combination of trastuzumab and pertuzumab for breast cancer was reported as a rare finding (one case of twenty-nine patients). To our knowledge, this is one of the first cases describing an ODS following therapy with pertuzumab, trastuzumab, and docetaxel.
  • ||||||||||  Evolution of Cancer Treatment Cost in the Last 36 Months: An Analysis from a Health Payer Perspective in Brazil () -  Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2321;    
    In this study, the cost of cancer treatment has increased by around 40%, especially in the last period, which coincides with the expansion of the national list of mandatory coverages, expanding access to new technologies. Molecular and immunological therapies have changed cancer treatment and improved patient outcomes and survival; however, these new treatments represent an additional challenge for the healthcare system.